RecruitingPhase 3NCT06742723
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Sponsor: AstraZeneca
Burlington, VT · +132 more sites